TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Presentation scheduled for Monday, January 13, 2025, at 4:30 PM PT
演示定於2025年1月13日星期一太平洋時間下午4:30舉行
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 13, 2025, at 4:30 PM PT.
紐約，2025年1月9日（全球新聞通訊社）-- TG Therapeutics, Inc.（納斯達克：TGTX）今天宣佈，公司董事長兼首席執行官Michael S. Weiss將在第43屆摩根大通醫療健康會議上進行演示。演示定於2025年1月13日星期一太平洋時間下午4:30進行。
A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at . A replay of the webcast will be available on TG's website following the event.
此次演示的直播網絡廣播將在公司網站投資者與媒體部分的活動頁面上提供。活動結束後，TG的網站將提供網絡廣播的重播。
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features, in Europe and the United Kingdom, respectively. For more information, visit , and follow us on Twitter @TGTherapeutics and on LinkedIn.
關於TG治療公司
TG治療公司是一家完全整合的商業階段生物製藥公司，專注於新型b細胞疾病治療方案的獲取、開發和商業化。除了包括幾種研究性藥物的研發管道外，TG還獲得了美國食品和藥物管理局（FDA）對BRIUMVI（ublituximab-xiiy）的批准，適用於成人複發性多發性硬化症（RMS）患者的治療，包括臨牀孤立綜合徵、複發性緩解性疾病和活動性繼發性進展性疾病，以及獲得歐洲委員會（EC）和英國藥品與醫療保健產品監管局（MHRA）對BRIUMVI的批准，以治療在歐洲和英國定義爲臨牀或影像特徵活躍疾病的成人RMS患者。如需更多信息，請訪問，並在Twitter @TGTherapeutics和LinkedIn上關注我們。
BRIUMVI is a registered trademark of TG Therapeutics, Inc.
BRIUMVI是TG Therapeutics, Inc.的註冊商標。
CONTACT:
聯繫方式：
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
投資者關係
電子郵件： ir@tgtxinc.com
電話：1.877.575.TGTX (8489)，選項 4
Media Relations
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
媒體關係
電子郵件： media@tgtxinc.com
電話：1.877.575.TGTX (8489)，選項6
譯文內容由第三人軟體翻譯。
